IN8bio, a Phase 1 biotech developing allogeneic gamma-delta T cell therapies for cancers, revived its IPO plans on Wednesday with a blank filing after postponing its $75 million IPO in November 2020. In its latest filing, the company indicated plans to raise up to $69 million, disclosed updated financials for the fiscal year ended December 31, 2020, and changed its underwriters, adding Cowen and Stifel and removing Barclays and Cantor Fitzgerald.
The company's pipeline contains lead candidates INB-200, which is currently in a Phase 1 trial for newly diagnosed glioblastoma, and INB-100, which is currently in a Phase 1 trial for patients with leukemia undergoing hematopoietic stem cell transplantation. Topline data is expected in 2021 and 2022, respectively.
The New York, NY-based company was founded in 2016 and plans to list on the Nasdaq under the symbol INAB. Cowen, Stifel, and Mizuho Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
